Government-Owned Inventions; Availability for Licensing, 62913-62914 [2016-21904]
Download as PDF
<![CDATA[
Federal Register / Vol. 81, No. 177 / Tuesday, September 13, 2016 / Notices
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Lhorne on DSK30JT082PROD with NOTICES
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Cell Replacement
Technology for Type 1 Diabetes (SBIR).
Date: October 4, 2016.
Time: 12:00 p.m. to 4:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Thomas A. Tatham, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7021, 6707 Democracy Boulevard,
Bethesda, MD 20892–5452, (301) 594–3993,
tathamt@mail.nih.gov.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; NIDDK Ancillary
Studies (R01).
Date: October 27, 2016.
Time: 11:00 a.m. to 12:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Telephone
Conference Call).
Contact Person: Jason D. Hoffert, Ph.D.,
Scientific Review Officer, Review Branch,
DEA, NIDDK, National Institutes of Health,
Room 7343, 6707 Democracy Boulevard,
Bethesda, MD 20817, 301–496–9010,
hoffertj@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: September 7, 2016.
David Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–21895 Filed 9–12–16; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
15:27 Sep 12, 2016
Jkt 238001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209
and 37 CFR part 404 to achieve
expeditious commercialization of
results of federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing and/or co-development.
ADDRESSES: Invention Development and
Marketing Unit, Technology Transfer
Center, National Cancer Institute, 9609
Medical Center Drive, Mail Stop 9702,
Rockville, MD, 20850–9702.
FOR FURTHER INFORMATION CONTACT:
Information on licensing and codevelopment research collaborations,
and copies of the U.S. patent
applications listed below may be
obtained by contacting: Attn. Invention
Development and Marketing Unit,
Technology Transfer Center, National
Cancer Institute, 9609 Medical Center
Drive, Mail Stop 9702, Rockville, MD,
20850–9702, Tel. 240–276–5515 or
email ncitechtransfer@mail.nih.gov. A
signed Confidential Disclosure
Agreement may be required to receive
copies of the patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Title of invention: Analogues of
Withanolide E Sensitize Cancer Cells to
Apoptosis.
Keywords: TRAIL, TLR3, apoptosis,
immunotherapy, tumor necrosis factor,
TNF.
Description of Technology: The tumor
necrosis factor (TNF)-related apoptosisinducing ligand (TRAIL) protein has
been a target of interest in cancer
therapy because it plays a large role in
inducing cell apoptosis in cancer cells
but not in normal cells. Although TRAIL
has been reported to successfully target
certain tumor cells which are resistant
to traditional chemotherapy or
radiation, TRAIL resistance has also
been widely observed. Similarly, Tolllike receptor (TLR) 3 ligands such as
poly I:C have also been reported to
promote apoptosis in certain cancer
cells, though the apoptotic signaling in
SUMMARY:
PO 00000
Frm 00060
Fmt 4703
Sfmt 4703
62913
most cancer cells was weak and was
only significant following longer term
incubations. Thus, there is a need to
develop compounds that can sensitize
cancer cells to apoptosis inducing
ligands, such as poly I:C and TRAIL.
In collaboration with the University of
Arizona, NCI investigators have
discovered a series of compounds in the
withanolide family that synergistically
enhance the response of cancer cells to
treatment with an apoptosis-inducing
ligand. The compounds each show a 4to 10-fold increase in potency compared
to withanolide E alone in promoting
death ligand-mediated cancer cell death.
One biotinylated analogue in particular
is at least 15-fold more potent than
withanolide E in promoting apoptosis in
human melanoma cells when used in
combination with either poly I:C or
TRAIL. A selection of active compounds
were tested in murine xenograft models
of human melanoma and showed
decreased tumor growth and tumor
regression.
Potential Commercial Applications
• Potential therapeutic for the
treatment of cancer either alone or in
combination with an apoptosis inducing
agent such as TRAIL receptor or TLR 3
agonists by directly promoting tumor
cell apoptosis.
• Possible indirect enhancement of
cancer immunotherapy due to release of
cancer cell antigens in the presence of
the powerful immune-adjuvant effects
of TLR3 agonists.
Value Proposition
• Withanolide E derivatives enhance
the anti-cancer activity of known
apoptosis inducing ligands such as
TRAIL or poly I:C and may be used to
enhance efficacy of TRAIL receptor or
poly I:C agonists that are currently
under development.
Development Stage: Pre-clinical (in
vivo validation).
Inventor(s): Thomas Sayers (NCI),
Alan Brooks (NCI), Curtis Henrich
(NCI), Poonam Tewary (NCI), James
McMahon (NCI), Leslie Gunatilaka
(University of Arizona), Ya-ming Xu
(University of Arizona), and E.M.
Kithsiri Wijeratne (University of
Arizona).
Intellectual Property: US Provisional
Application No. 62/292,974, entitled
‘‘Method of Sensitizing Cancer Cells to
The Cytotoxic Effects of Apoptosis
Inducing Ligands in Cancer Treatment,’’
filed February 9, 2016.
Publications
1. Tewary P., Gunatilaka A.A. and
Sayers T.J. (2016) Using natural
products to promote caspase-8-
E:\FR\FM\13SEN1.SGM
13SEN1
62914
Federal Register / Vol. 81, No. 177 / Tuesday, September 13, 2016 / Notices
dependent cancer cell death. Cancer
Immunol Immunother. doi:10.1007/
s00262–016–1855–0.
Related Technologies: US Patent
9,238,069 (HHS Ref. No. E–050–2010)
entitled ‘‘Use of withanolides to
sensitize cancer cells to the cytotoxic
effects of Apo2L/TRAIL’’ issued January
19, 2016.
Collaboration Opportunity:
Researchers at the NCI seek licensing
and/or co-development research
collaborations for development of
withanolide E analogues for the
treatment of cancer.
Contact Information: Requests for
copies of the patent application or
inquiries about licensing, research
collaborations, and co-development
opportunities should be sent to John D.
Hewes, Ph.D., email: john.hewes@
nih.gov.
Dated: September 6, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology
Transfer Center, National Cancer Institute.
[FR Doc. 2016–21904 Filed 9–12–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Mental Health;
Notice of Closed Meeting
Lhorne on DSK30JT082PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Mental Health Initial Review Group; Mental
Health Services Research Committee.
Date: October 7, 2016.
Time: 8:00 a.m. to 2:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Monaco, 700 F Street NW.,
Washington, DC 20001.
Contact Person: Aileen Schulte, Ph.D.,
Scientific Review Officer, Division of
Extramural Activities, National Institute of
Mental Health, NIH, Neuroscience Center,
6001 Executive Blvd., Room 6136, MSC 9606,
VerDate Sep<11>2014
15:27 Sep 12, 2016
Jkt 238001
Bethesda, MD 20852, 301–443–1225,
aschulte@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.242, Mental Health Research
Grants, National Institutes of Health, HHS)
Dated: September 7, 2016.
Carolyn A. Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–21897 Filed 9–12–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Environmental
Health Sciences; Notice of Closed
Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel; Superfund Hazardous
Substance Research and Training Program.
Date: September 27–29, 2016.
Time: 8:30 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Sheraton Imperial Hotel and
Convention Center, 4700 Emperor Blvd.,
Durham, NC 27703.
Contact Person: Linda K. Bass, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research and
Training, Nat. Institute Environmental Health
Sciences, 530 Davis Drive, Room 3074, P.O.
Box 12233, MD EC–30, Research Triangle
Park, NC 27709, (919) 541–1307, bass@
niehs.nih.gov.
Name of Committee: National Institute of
Environmental Health Sciences Special
Emphasis Panel; Superfund Hazardous
Substance Research and Training Program.
Date: September 29, 2016.
Time: 1:30 p.m. to 4:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: Sheraton Imperial Center, One
Europa Drive, Chapel Hill, NC 27517.
Contact Person: Leroy Worth, Ph.D.,
Scientific Review Officer, Scientific Review
Branch, Division of Extramural Research and
Training, Nat. Institute of Environmental
PO 00000
Frm 00061
Fmt 4703
Sfmt 4703
Health Sciences, 530 Davis Drive, Room
3171, P.O. Box 12233, MD EC–30, Research
Triangle Park, NC 27709, (919) 541–0670,
worth@niehs.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.115, Biometry and Risk
Estimation—Health Risks from
Environmental Exposures; 93.142, NIEHS
Hazardous Waste Worker Health and Safety
Training; 93.143, NIEHS Superfund
Hazardous Substances—Basic Research and
Education; 93.894, Resources and Manpower
Development in the Environmental Health
Sciences; 93.113, Biological Response to
Environmental Health Hazards; 93.114,
Applied Toxicological Research and Testing,
National Institutes of Health, HHS)
Dated: September 7, 2016.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2016–21896 Filed 9–12–16; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development Initial
Review Group; Health, Behavior, and Context
Subcommittee.
Date: October 14, 2016.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW.,
Washington, DC 20015.
Contact Person: Priscah Mujuru, DRPH,
MPH, Scientific Review Officer, Scientific
Review Branch, Eunice Kennedy Shriver
National Institute of Child Health and
Human Development, NIH, 6710B Bethesda
Drive, 2221A, Bethesda, MD 20892, 301–
435–6908, mujurup@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
E:\FR\FM\13SEN1.SGM
13SEN1
]]>Agencies
[Federal Register Volume 81, Number 177 (Tuesday, September 13, 2016)]
[Notices]
[Pages 62913-62914]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-21904]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing and/or co-development in the
U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve
expeditious commercialization of results of federally-funded research
and development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing and/or co-development.
ADDRESSES: Invention Development and Marketing Unit, Technology
Transfer Center, National Cancer Institute, 9609 Medical Center Drive,
Mail Stop 9702, Rockville, MD, 20850-9702.
FOR FURTHER INFORMATION CONTACT: Information on licensing and co-
development research collaborations, and copies of the U.S. patent
applications listed below may be obtained by contacting: Attn.
Invention Development and Marketing Unit, Technology Transfer Center,
National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702,
Rockville, MD, 20850-9702, Tel. 240-276-5515 or email
ncitechtransfer@mail.nih.gov. A signed Confidential Disclosure
Agreement may be required to receive copies of the patent applications.
SUPPLEMENTARY INFORMATION: Technology description follows.
Title of invention: Analogues of Withanolide E Sensitize Cancer
Cells to Apoptosis.
Keywords: TRAIL, TLR3, apoptosis, immunotherapy, tumor necrosis
factor, TNF.
Description of Technology: The tumor necrosis factor (TNF)-related
apoptosis-inducing ligand (TRAIL) protein has been a target of interest
in cancer therapy because it plays a large role in inducing cell
apoptosis in cancer cells but not in normal cells. Although TRAIL has
been reported to successfully target certain tumor cells which are
resistant to traditional chemotherapy or radiation, TRAIL resistance
has also been widely observed. Similarly, Toll-like receptor (TLR) 3
ligands such as poly I:C have also been reported to promote apoptosis
in certain cancer cells, though the apoptotic signaling in most cancer
cells was weak and was only significant following longer term
incubations. Thus, there is a need to develop compounds that can
sensitize cancer cells to apoptosis inducing ligands, such as poly I:C
and TRAIL.
In collaboration with the University of Arizona, NCI investigators
have discovered a series of compounds in the withanolide family that
synergistically enhance the response of cancer cells to treatment with
an apoptosis-inducing ligand. The compounds each show a 4- to 10-fold
increase in potency compared to withanolide E alone in promoting death
ligand-mediated cancer cell death. One biotinylated analogue in
particular is at least 15-fold more potent than withanolide E in
promoting apoptosis in human melanoma cells when used in combination
with either poly I:C or TRAIL. A selection of active compounds were
tested in murine xenograft models of human melanoma and showed
decreased tumor growth and tumor regression.
Potential Commercial Applications
Potential therapeutic for the treatment of cancer either
alone or in combination with an apoptosis inducing agent such as TRAIL
receptor or TLR 3 agonists by directly promoting tumor cell apoptosis.
Possible indirect enhancement of cancer immunotherapy due
to release of cancer cell antigens in the presence of the powerful
immune-adjuvant effects of TLR3 agonists.
Value Proposition
Withanolide E derivatives enhance the anti-cancer activity
of known apoptosis inducing ligands such as TRAIL or poly I:C and may
be used to enhance efficacy of TRAIL receptor or poly I:C agonists that
are currently under development.
Development Stage: Pre-clinical (in vivo validation).
Inventor(s): Thomas Sayers (NCI), Alan Brooks (NCI), Curtis Henrich
(NCI), Poonam Tewary (NCI), James McMahon (NCI), Leslie Gunatilaka
(University of Arizona), Ya-ming Xu (University of Arizona), and E.M.
Kithsiri Wijeratne (University of Arizona).
Intellectual Property: US Provisional Application No. 62/292,974,
entitled ``Method of Sensitizing Cancer Cells to The Cytotoxic Effects
of Apoptosis Inducing Ligands in Cancer Treatment,'' filed February 9,
2016.
Publications
1. Tewary P., Gunatilaka A.A. and Sayers T.J. (2016) Using natural
products to promote caspase-8-
[[Page 62914]]
dependent cancer cell death. Cancer Immunol Immunother. doi:10.1007/
s00262-016-1855-0.
Related Technologies: US Patent 9,238,069 (HHS Ref. No. E-050-2010)
entitled ``Use of withanolides to sensitize cancer cells to the
cytotoxic effects of Apo2L/TRAIL'' issued January 19, 2016.
Collaboration Opportunity: Researchers at the NCI seek licensing
and/or co-development research collaborations for development of
withanolide E analogues for the treatment of cancer.
Contact Information: Requests for copies of the patent application
or inquiries about licensing, research collaborations, and co-
development opportunities should be sent to John D. Hewes, Ph.D.,
email: john.hewes@nih.gov.
Dated: September 6, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology Transfer Center, National
Cancer Institute.
[FR Doc. 2016-21904 Filed 9-12-16; 8:45 am]
BILLING CODE 4140-01-P
